AU2005219839B9 - Natural IgM antibodies and inhibitors thereof - Google Patents

Natural IgM antibodies and inhibitors thereof Download PDF

Info

Publication number
AU2005219839B9
AU2005219839B9 AU2005219839A AU2005219839A AU2005219839B9 AU 2005219839 B9 AU2005219839 B9 AU 2005219839B9 AU 2005219839 A AU2005219839 A AU 2005219839A AU 2005219839 A AU2005219839 A AU 2005219839A AU 2005219839 B9 AU2005219839 B9 AU 2005219839B9
Authority
AU
Australia
Prior art keywords
peptide
antibody
seq
igm
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005219839A
Other languages
English (en)
Other versions
AU2005219839A1 (en
AU2005219839B2 (en
Inventor
Michael C. Carroll
Herbert B. Hechtman
Francis D. Moore Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Harvard University
Original Assignee
Brigham and Womens Hospital Inc
Immune Disease Institute Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Immune Disease Institute Inc, Harvard University filed Critical Brigham and Womens Hospital Inc
Publication of AU2005219839A1 publication Critical patent/AU2005219839A1/en
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC., IMMUNE DISEASE INSTITUTE, INC, PRESIDENT AND FELLOWS OF HARVARD COLLEGE reassignment THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Request for Assignment Assignors: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH
Application granted granted Critical
Publication of AU2005219839B2 publication Critical patent/AU2005219839B2/en
Publication of AU2005219839B9 publication Critical patent/AU2005219839B9/en
Priority to AU2012200909A priority Critical patent/AU2012200909B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2005219839A 2004-03-01 2005-03-01 Natural IgM antibodies and inhibitors thereof Ceased AU2005219839B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012200909A AU2012200909B2 (en) 2004-03-01 2012-02-16 Natural lgM antibodies and inhibitors thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54912304P 2004-03-01 2004-03-01
US60/549,123 2004-03-01
US58864804P 2004-07-16 2004-07-16
US60/588,648 2004-07-16
PCT/US2005/006276 WO2005085288A2 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012200909A Division AU2012200909B2 (en) 2004-03-01 2012-02-16 Natural lgM antibodies and inhibitors thereof

Publications (3)

Publication Number Publication Date
AU2005219839A1 AU2005219839A1 (en) 2005-09-15
AU2005219839B2 AU2005219839B2 (en) 2011-11-24
AU2005219839B9 true AU2005219839B9 (en) 2011-12-22

Family

ID=34922704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005219839A Ceased AU2005219839B9 (en) 2004-03-01 2005-03-01 Natural IgM antibodies and inhibitors thereof

Country Status (9)

Country Link
US (5) US7442783B2 (https=)
EP (2) EP2290077B1 (https=)
JP (3) JP5557982B2 (https=)
AT (1) ATE498010T1 (https=)
AU (1) AU2005219839B9 (https=)
CA (1) CA2560066A1 (https=)
DE (1) DE602005026260D1 (https=)
IL (1) IL177825A (https=)
WO (1) WO2005085288A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
ATE498010T1 (de) 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
US8324352B2 (en) 2009-12-07 2012-12-04 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
KR20130108104A (ko) * 2010-06-03 2013-10-02 아브락시스 바이오사이언스, 엘엘씨 말초혈 ｓｐａｒｃ 결합 항체와 이들의 용도
WO2014055392A2 (en) * 2012-10-01 2014-04-10 Decimmune Therapeutics, Inc. Method of protecting cardiac function
JP6162319B2 (ja) 2013-03-12 2017-07-12 デシミューン セラピューティクス，インコーポレイテッド ヒト化抗ｎ２抗体
JP6551825B2 (ja) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 クロマチン構造制御剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008756A1 (en) * 1989-12-12 1991-06-27 Biomedical Research Institute Novel malarial sporozoite peptide antigens
WO2000032825A2 (en) * 1998-12-03 2000-06-08 Phagetech, Inc. Development of anti-microbial agents based on bacteriophage genomics
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001088088A2 (en) * 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001093892A1 (en) * 2000-06-08 2001-12-13 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
BR8907069A (pt) 1988-09-06 1991-01-02 Asarco Inc Dispositivo queimador e metodo para fundir cobre
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP0502060A4 (en) 1989-11-13 1993-05-05 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
ES2204910T3 (es) 1992-10-01 2004-05-01 The Trustees Of Columbia University In The City Of New York Bibliotecas quimicas combinatorias complejas codificadas con señales.
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
AU2407600A (en) 1999-01-15 2000-08-01 Craig S. Echt Microsatellite dna markers and uses thereof
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
US6355481B1 (en) * 1999-06-18 2002-03-12 Emory University Hybridoma cell line and monoclonal antibody for huntingtin protein
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001296594A1 (en) * 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AU2002327164A1 (en) * 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040131607A1 (en) 2001-06-08 2004-07-08 Carroll Michael C. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
WO2003055982A2 (en) * 2001-12-21 2003-07-10 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
EP1465906A1 (en) * 2001-12-21 2004-10-13 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ATE498010T1 (de) * 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
US20100136684A1 (en) 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008756A1 (en) * 1989-12-12 1991-06-27 Biomedical Research Institute Novel malarial sporozoite peptide antigens
WO2000032825A2 (en) * 1998-12-03 2000-06-08 Phagetech, Inc. Development of anti-microbial agents based on bacteriophage genomics
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001088088A2 (en) * 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001093892A1 (en) * 2000-06-08 2001-12-13 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL accession no. AACD01000116 24 April 2003 *
DATABASE EMBL accession no. AB957589 21 March 2001 *
DATABASE EMBL accession no. AY122933 5 July 2002 *

Also Published As

Publication number Publication date
WO2005085288A3 (en) 2006-08-03
IL177825A0 (en) 2006-12-31
JP5557982B2 (ja) 2014-07-23
CA2560066A1 (en) 2005-09-15
US7442783B2 (en) 2008-10-28
EP2290077B1 (en) 2016-01-27
US20050276811A1 (en) 2005-12-15
IL177825A (en) 2013-02-28
US20170342109A1 (en) 2017-11-30
EP1725659A2 (en) 2006-11-29
DE602005026260D1 (de) 2011-03-24
US20160280740A1 (en) 2016-09-29
EP1725659B1 (en) 2011-02-09
HK1154904A1 (en) 2012-05-04
ATE498010T1 (de) 2011-02-15
WO2005085288A2 (en) 2005-09-15
US9657060B2 (en) 2017-05-23
JP5618852B2 (ja) 2014-11-05
EP2290077A3 (en) 2011-05-18
US9914751B2 (en) 2018-03-13
US20090176966A1 (en) 2009-07-09
JP2008504807A (ja) 2008-02-21
JP2014155497A (ja) 2014-08-28
AU2005219839A1 (en) 2005-09-15
JP2011139704A (ja) 2011-07-21
US20140127214A1 (en) 2014-05-08
AU2005219839B2 (en) 2011-11-24
EP2290077A2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
US9914751B2 (en) Natural IGM antibodies and inhibitors thereof
JP2002531065A (ja) 疾患の診断及び治療において有用な生物学的材料及び方法
TR201812636T4 (tr) İnsan anti-tau antikorları.
US12398201B2 (en) Tau single domain antibodies
KR20230082071A (ko) SARS-CoV-2 변이체들에 특이적으로 결합하는 항체
US20100136684A1 (en) Natural IgM Antibodies
US20240199725A1 (en) Human antibody targeting covid-19 virus
US20040131607A1 (en) Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
AU2012200909B2 (en) Natural lgM antibodies and inhibitors thereof
CN1977043B (zh) 天然IgM抗体及其抑制剂
HK1154904B (en) Natural igm antibodies and inhibitors thereof
EP1286682B1 (en) Methods and compositions for inhibiting immunoglobulin-mediated-reperfusion injury
KR20220163625A (ko) 신규한 코로나-19 바이러스 표적 인간 항체
KR20220048028A (ko) 항-cd19 항체 및 그의 용도
HK1150533A (en) Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE BRIG

Free format text: FORMER NAME: PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE BRIGHAM AND WOMEN'S HOSPITAL, INC.; THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired